Docket No. PRD0039USN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Battista et al.

Serial No.: 10/656,934

Art Unit: 1625

Filed

: September 5, 2003

Examiner: Rita I. Desai

: HYDROXY-ALKYL

For

SUBSTITUTED 1.3.8-

TRIAZSPIRO[4,5] DECAN-4-ONE DERIVATIVES USEFUL FO THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

(Date of Deposit)

Hal Brent Woodrow
(Name of applicant, assignee, or Registered Representative)

January 19, 2005

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the aboveidentified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

01/25/2005 AADDF01 00000027 100750 10656934 180.00 DA 01 FC:1806

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
§1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under §1.114, no additional
fee is required.

- - Statement in Accordance with §1.97(e)
 (attached); or
 - Please charge Deposit Account No. 10-0750/PRD0039USNP/HBW the fee of \$180.00 as set forth in \$1.17(p).
- In accordance with §1.97(c), this Information
 Disclosure Statement is being filed after the period set forth
 in §1.97(b) above but before the mailing date of either a Final
 Action under §1.113 or a Notice of Allowance under §1.311, or
 an action that otherwise closes prosecution and that it is
 accompanied by one of:

. \square	Statement in Accordance with §1.97(e)
	(attached); or
	Please charge Deposit Account No. 10-
	0750/ / the fee of $$180.00$ as set forth
	in §1.17(p).
□ In ac	ccordance with §1.97(d), this Information
Disclosure Stat	ement is being filed after the mailing date of
either a Final	Action under §1.113 or a Notice of Allowance
under §1.311 b	out before the payment of the Issue Fee.
Applicant(s) he	ereby petition(s) for consideration of this
Information Dis	sclosure Statement. Included are: Statement in
Accordance with	1 §1.97(e) as set forth below and the fee of
\$180.00 as set	forth in §1.17(p).
- 100	es of each of the references listed on the
attached Form F	PTO-1449 are enclosed herewith.
☐ Copie	es of references listed on the attached Form PTO
1449 are enclos	ed herewith EXCEPT THAT:
	In view of the voluminous nature of references
	[list as appropriate], and the likelihood that
	these references are available to the Examiner,
	copies are not enclosed herewith.
	If any of the foregoing publications are not
	available to the Examiner, Applicant will
	endeavor to supply copies at the Examiner's
	request.

Copies of only foreign patent documents and nonpatent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).

- ☐ There are no listed references which are not in the English language.

 ☑ The relevance of those listed references which are not in the English language can be found in an English-language abstract contained therein.

 ☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the
- Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD0039USNP/HBW. This form is submitted in triplicate.

Respectfully submitted,

Hal B. Woodrow
Reg. No. 32,501
Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-2976 DATED: January 19, 2005

attached Submission Under MPEP 609 D.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of Information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 2

01/96337

A1

a collection of Information unless is degiage; a valid OWS control number.

Application Number | 10/656,938

Filling Date | September 5, 2003

First Named Inventor | Battlista et al.

Group Art Unit | 1625

Examiner Name | Rita J. Desai

Attorney Docket Number | PRD0039USNP

U.S. PATENT DOCUMENTS

		U.S. Faterit Docume	an		Date of Publication		
Examiner Initials	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	of Cited Documen		
		6,113,527	Α	Hoffmann-La Roche Inc.	9-05-2000		
			-				
							_
	<u> </u>		FOR	EIGN PATENT DOCUMENTS			-
		Foreign Patent Docu	ıment	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No.1	Office ³ Number ⁴	Applicant of Cited Document mm-dd-yyyy pas		passages or relevant figures appear	T ⁰	

	wo	03/010168	A1	Banyu Pharmaceutical Co., Ltd.	7-23-2001	
	wo	02/085355	A1	Euro-Celtique, S.A.	10-31-2002	
 			ļ			
					1	

Banyu Pharmaceutical Co., Ltd.

6-08-2001

Examine	Date	
Signature	Considered	

and not considered. Include copy of this form with next communication to applicant.

Linkique clastion designation number. See a tabched Kinds of U.S. Patent Documents, a Entire Office that issued the document, by the two-letter
code (WIPD Standard ST.3), 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial
number of the patent document, 4 Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if
possible. 4 Applicant is to place a check mark here if English language Translation is attochant is to place a check mark here if English language Translation is attochant.

possible. Applicant is to place a check mark here if English larguage Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO. Commissioner for Patents, P.O. Box 1450, Alexandric, VA 22313-1409.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002, OMB 0551-0031
U.S. Patent and Tredemark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number.

INFORMATION DISC STATEMENT BY AF

(use as many sheets as neces: Sheet 2 of 2

	Application Number	10/656,934
	Filing Date	September 5, 2003
CLOSURE	First Named Inventor	Battista et al.
DUICANT	Group Art Unit	1625
PPLICANT	Examiner Name	Rita J. Desai
sary) .	Attorney Docket Number	PRD0039USNP

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T²
Initials*	No.1	publisher, city and/or country where published	
		Ronzoni, Silvano et al., "Lead generation and lead optimization approaches in the discovery of selective, non-peptide ORL-1 receptor agonists and antagonists," Exp. Opin. Ther. Patents, 2001, (11)4, pp. 525-546	
		Zeverl, Nurulain, "Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: Research tools and potential therapeutic agents," Life Sciences 73 (2003), pp. 663-678	
		Jenck, Francois et al., "A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: Anxiolytic profile in the rat," PNAS, April 25, 2000, vol. 97, no. 9, pp. 4938-4953	
		Thomsen, Chrisian et al., "(8-Naphthalen-1-yimethyl-4-oxo-1-phenyl-1,3.8-triaza-spiro[4.5]-dec-3-yi)-acetic acid methyl ester (NNC 83-0532) is a novel potent nociceptin receptor agonist," British Journal of Pharmacology (2000) 131, 903-908	
			_
	Ė		
		AND	

Examiner	Date	
Signatum	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

i Unique citation designation number, 2 Applicant is to place a check mark here if English language Translation is attached.

Buden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the summent of the source required to complete this form afhould be sent to the Chief Information Officer, U. S. Patent and Trademark. Office, Washington, DC 2023.

DO NOT SEND PEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.